Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Crystec Pharma
Crystec Pharma
Activities:
Ingredients
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Distribution
Manufacturing Chemist LIVE 2022 in review (part II)
Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond
Research & Development
CrystecPharma and Biosidus collaborate on biotherapeutics
The first programme in the cooperation will develop a dry powder preparation of teriparatide for the treatment of osteoporosis
Research & Development
CrystecPharma to help develop inhaled formulation for respiratory conditions
SignalRx's SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor with a synergistic action on two pathways associated with the development of lung cancer and idiopathic pulmonary fibrosis
Finance
Crystec launch R&D centre in Jiangsu province, China
The Haimen facility will support the company’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology
Manufacturing
Crystec wins Contract Services and Outsourcing Award at CPhI Awards
Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing
Media
Major progress in next generation medicine initiative
Juniper Pharma Services has reached a key milestone in its work with CrystecPharma and the Advanced Manufacturing Supply Chain Initiative (AMSCI) to create a new platform to accelerate drug development
Manufacturing
New video from Crystec highlights mSAS technology
mSAS particle engineering versus conventional micronisation
Subscribe now